Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Britschgi

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 12, 2021
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II TrialSacha I Rothschild, Alfred Zippelius, Eric I Eboulet, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical PracticeXiuning Le, Hiroshi Sakai, Enriqueta Felip, et al.
Pageof 5